355 related articles for article (PubMed ID: 26615988)
1. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Strickler JH; Wu C; Bekaii-Saab T
Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
[TBL] [Abstract][Full Text] [Related]
3. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Lee HM; Morris V; Napolitano S; Kopetz S
Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
[TBL] [Abstract][Full Text] [Related]
4. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
[No Abstract] [Full Text] [Related]
5. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
6. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.
Temraz S; Alameddine R; Shamseddine A
Curr Opin Oncol; 2015 May; 27(3):276-81. PubMed ID: 25774859
[TBL] [Abstract][Full Text] [Related]
7. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
Wong V; Lee M; Wong R; Tie J; Shapiro J; Desai J; Nott L; Steel S; Burge M; Ma B; Khattak A; Hong W; Gibbs P
Target Oncol; 2021 Mar; 16(2):227-236. PubMed ID: 33599905
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
10. BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications.
Angerilli V; Sabella G; Centonze G; Lonardi S; Bergamo F; Mangogna A; Pietrantonio F; Fassan M; Milione M
Crit Rev Oncol Hematol; 2022 Apr; 172():103647. PubMed ID: 35248712
[TBL] [Abstract][Full Text] [Related]
11. Treatment options in BRAF-mutant metastatic colorectal cancer.
Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
[TBL] [Abstract][Full Text] [Related]
12. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
13. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.
Sanz-Garcia E; Argiles G; Elez E; Tabernero J
Ann Oncol; 2017 Nov; 28(11):2648-2657. PubMed ID: 29045527
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Cohen R; Liu H; Fiskum J; Adams R; Chibaudel B; Maughan TS; Van Cutsem E; Venook A; Douillard JY; Heinemann V; Ja Punt C; Falcone A; Bokemeyer C; Kaplan R; Lenz HJ; Koopman M; Yoshino T; Zalcberg J; Grothey A; de Gramont A; Shi Q; André T
J Natl Cancer Inst; 2021 Oct; 113(10):1386-1395. PubMed ID: 33734401
[TBL] [Abstract][Full Text] [Related]
18. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
19. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
20. Encorafenib, binimetinib and cetuximab combined therapy for patients with
Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]